sacituzumab tirumotecan + QL1706

**sacituzumab tirumotecan + QL1706** is an investigational combination therapy being evaluated for the treatment of recurrent or metastatic cervical cancer. The regimen consists of **sacituzumab tirumotecan** (also known as SKB264 or MK-2870), a TROP2-directed antibody-drug conjugate (ADC), and **QL1706**, a bifunctional antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Sacituzumab tirumotecan comprises a humanized anti-TROP2 monoclonal antibody conjugated to a belotecan-derived topoisomerase I inhibitor payload (KL610023) via a novel sulfonyl pyrimidine-CL2A-carbonate linker. QL1706 acts as a dual checkpoint inhibitor to enhance the anti-tumor immune response. This combination is currently being studied in a Phase II clinical trial sponsored by Fujian Cancer Hospital for patients who have failed prior platinum-based therapy. Although the input name mentions sacituzumab govitecan, the specific trial context clarifies that sacituzumab tirumotecan is the ADC utilized in this regimen.

Other names

sacituzumab govitecan-Fujian Cancer Hospital-cervical cancerSacituzumab Tirumotecan + QL1706